Trial reportBMC medicine2025
Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.
Trial report in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification ofTranslational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundPatients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) face limited treatment options and poor outcomes. Preclinical evidence supports chemoimmunotherapy as a conversion therapy; therefore, this study aims to evaluate the efficacy and safety of preoperative camrelizumab with paclitaxel and nedaplatin.
methodsPatients received a combination of camrelizumab (200 mg), paclitaxel (155 mg/m
resultsThis trial enrolled 141 patients with unresectable ESCC (132 locally advanced [M0], 9 metastatic [M1]) with a median follow-up of 32.2 months. Post-induction ORR was 56.7%. The intention-to-treat (ITT) conversion rate reached 48.9% overall and 50.0% (66/132) in M0 patients (R0: 100%; pathological complete response (pCR): 20.9%; major pathological response: 55.2%). One-year OS was 78.7%. Surgical conversion significantly improved survival overall (median OS: not reached (NR) vs. 14.1 months; hazard ratio (HR) = 0.22; 95% CI, 0.13-0.37; P < 0.0001), with further benefit in objective responders (median OS: NR vs. 20.9 months; HR = 0.30; 95% CI, 0.14-0.61; P < 0.001). Approximately 75.9% of patients experienced treatment-related adverse events (TRAEs), predominantly mild to moderate. Pan-lactylation levels were significantly elevated in non-pCR ESCC compared to pCR tissues. A peritumoral radiomic features-derived model effectively stratified patients into distinct groups with significantly different OS and DFS.
conclusionsThe chemoimmunotherapy regimen shows promising efficacy as a conversion therapy in improving surgical resectability and survival outcomes with manageable TRAEs, and does not delay surgery. TRIAL REGISTRATION NUMBER: ChiCTR2100046355.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.